J9024 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 J9024 summary

J9024 is a HCPCS Level II J-code used to bill atezolizumb 5mg hya-tqjs, billed per 5 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9024: Tecentriq Hybreza

Code J9024 Billing unit 5 MG Payment limit $32.554/unit NDC-Crosswalk 1 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9024

DescriptorInj atezolizumb 5mg hya-tqjs

Billing unit5 MG

Payment limit / unit$32.554

Est. ASP / unit$30.711 est.

Mapped NDCs1

Data periodQ3 2026

Last updated2026-08-20

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).

Medicare payment limit / unit

$32.554

Est. ASP / unit

$30.711 est.

Est. after 2% sequester

$31.903

HCPCS dosage

5 MG

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9024 = 5 mg. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (mg) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9024 WITH EST. MEDICARE PAY

1 NDC map to J9024. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($32.554/unit) × that package's bill units.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	Est. pay / pkg	NADAC / unit	Status	Source
50242-0933-01	Tecentriq Hybreza atezolizumab and hyaluronidase-tqjs 1875 mg/15mL; 30000 U/15mL INJECTION	Genentech,	1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01...	1875 mg/15mL; 30000 U/15mL	375	$12,207.75	—	● Active	CMS + PDAC

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse J9024 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with J9024. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from J9024
J9022	Inj, atezolizumab,10 mg	10 MG	$96.546	Different billing unit — 10 MG vs 5 MG

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period

Total Part B spend

$8.26M

Claims

688

Beneficiaries

289

Spend / beneficiary

$28,594.34

Spend / claim

$12,011.29

Trend by period

Where J9024 ranks among Part B drugs · 2026 (Q1) · neighbors ±5

Total spending — #198 of 824

#193 QUTENZA J7336 $8.51M #194 DEXTENZA J1096 $8.47M #195 XOFIGO A9606 $8.42M #196 TYENNE AUTOINJECTOR* Q5135 $8.37M #197 TNKASE J3101 $8.36M #198 TECENTRIQ HYBREZA J9024 $8.26M #199 XEOMIN J0588 $8.12M #200 ADMELOG SOLOSTAR* J1817 $8M #201 PEMGARDA (EUA) Q0224 $7.66M #202 VPRIV J3385 $7.61M #203 HUMATE-P J7187 $7.45M

Total claims — #414 of 824

#409 ENGERIX-B ADULT(9074... 90740 724 #410 GAMMAPLEX J1557 711 #411 AFFINITY1 SQUARE CM*... Q4159 710 #412 ALTUVIIIO J7214 704 #413 COLUMVI J9286 689 #414 TECENTRIQ HYBREZA J9024 688 #415 HYPERRAB 90375 686 #416 UPLIZNA J1823 686 #417 YONDELIS J9352 684 #418 ABILIFY MAINTENA J0401 670 #419 VIVITROL J2315 668

Full breakdown by period (2)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2026 (Q1)	$8.26M	289	688	$28,594.34	$12,011.29
2025 (Q1-Q4)	$17.26M	351	1,488	$49,161.37	$11,596.53

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.

Allowed charges

$7.6M

Medicare paid

$5.94M

Submitted services

252,943

Denial rate

4.0%

Allowed / service

$31.31

Submitted charges

$20.97M

Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

📊 What bills under J9024

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient

atezolizumab and hyaluronidase-tqj... 1

NDC products by labeler

Genentech, Inc. 1

🔗 Related NDC directory pages

🧪 All Atezolizumab And Hyaluronidase-Tqjs NDCsIngredient 🏭 All Genentech, labeler NDCsLabeler 50242 📚 All Endoglycosidase NDCsDrug class 📚 All Programmed Death Receptor-1 Blocking Antibody NDCsDrug class

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Not available in current dataset

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Q3 2026 · as of 2026-08-20

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)

1 NDC mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2026

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9024 billing FAQ

What is HCPCS code J9024?

J9024 is a HCPCS Level II J-code used to bill Inj atezolizumb 5mg hya-tqjs under Medicare Part B and most medical (not pharmacy) benefits.

What is the billing unit for J9024?

One unit of J9024 represents 5 MG. Report the number of units equal to the dose administered divided by 5 MG.

How many units of J9024 should I bill?

Divide the dose administered by the code's unit size (5 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.

How much does Medicare pay for J9024?

The Medicare Part B payment limit is $32.554 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $31.903 per unit. Payment limits are revised quarterly.

Which NDCs bill under J9024?

1 NDC currently map to J9024 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean J9024 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

J9024 – Inj atezolizumb 5mg hya-tqjs · NDC Crosswalk & Billing Units